Novartis Ag (NVS) Non-Current Debt (2009 - 2026)
Novartis Ag (NVS) posted Non-Current Debt of $37.5 billion for Q2 2026, up 34.2% sequentially from $27.9 billion in Q4 2025, and up 66.84% YoY from $22.5 billion in Q2 2025.
Novartis Ag (NVS) Non-Current Debt (2009 - 2026) Analysis & Trends
Novartis Ag has reported Non-Current Debt for 18 years, with the latest figure at $37.5 billion in Q2 2026.
- Quarterly Non-Current Debt rose 66.84% year-over-year to $37.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.5 billion (up 66.84% YoY) and the FY2025 annual result came in at $27.9 billion, up 30.75% from the prior year.
- Non-Current Debt improved to $37.5 billion in Q2 2026 per NVS's latest filing, from $27.9 billion in the prior quarter.
- Over five years, Non-Current Debt peaked at $37.5 billion in Q2 2026 and troughed at $18.3 billion in Q2 2023.
- A 5-year average of $23.1 billion and a median of $21.4 billion in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2026: Non-Current Debt retreated 17.87% in 2023, then jumped 66.84% in 2026.
- Over 5 years, Non-Current Debt stood at $20.2 billion in 2022, then slipped by 8.93% to $18.4 billion in 2023, then rose by 15.89% to $21.4 billion in 2024, then soared by 30.75% to $27.9 billion in 2025, then soared by 34.2% to $37.5 billion in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $37.5 billion, $27.9 billion, and $22.5 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 469.59 Bn | 463.02 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 375.61 Bn | 368.47 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 302.64 Bn | 294.95 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.53 Bn | 252.63 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 236.78 Bn | 222.79 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 183.22 Bn | 180.04 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 160.17 Bn | 148.47 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.95 Bn | 101.79 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 55.19 Bn | 47.81 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.49 Bn |
| Dec 31, 2025 | 27.94 Bn |
| Jun 30, 2025 | 22.47 Bn |
| Dec 31, 2024 | 21.37 Bn |
| Jun 30, 2024 | 19.66 Bn |
| Dec 31, 2023 | 18.44 Bn |
| Jun 30, 2023 | 18.26 Bn |
| Dec 31, 2022 | 20.24 Bn |
| Jun 30, 2022 | 22.23 Bn |
| Dec 31, 2021 | 22.90 Bn |
| Jun 30, 2021 | 24.83 Bn |
| Dec 31, 2020 | 26.26 Bn |
| Jun 30, 2020 | 23.96 Bn |
| Dec 31, 2019 | 20.35 Bn |
| Jun 30, 2019 | 20.36 Bn |
| Mar 31, 2019 | 338.00 Mn |
| Dec 31, 2018 | 22.47 Bn |
| Jun 30, 2018 | 22.76 Bn |
| Dec 31, 2017 | 23.22 Bn |
| Dec 31, 2016 | 17.90 Bn |